A survey by Neurocrine Biosciences reveals that about 20% of working adults with tardive dyskinesia (TD) quit their jobs due to untreated involuntary movements, missing an average of 8 hours of work or school weekly before treatment. The findings highlight the significant impact of TD on employment and daily life, emphasizing the need for early diagnosis and appropriate treatment. Despite guidelines recommending FDA-approved VMAT2 inhibitors for moderate to severe TD, only 10% receive such treatment. The survey underscores the importance of awareness during Tardive Dyskinesia Awareness Week to improve screening and management of this condition affecting over 800,000 U.S. adults.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hype...
Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adr...
